LogicBio Therapeutics, Inc.

NasdaqGM:LOGC Rapport sur les actions

Capitalisation boursière : US$68.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

LogicBio Therapeutics Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

37.7%

Ratio d'endettement

US$5.93m

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$30.78m
Fonds propresUS$15.74m
Total du passifUS$22.86m
Total des actifsUS$38.60m

Mises à jour récentes de la santé financière

Recent updates

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

Oct 03

Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

Aug 20
Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 18
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

LogicBio GAAP EPS of -$0.15, revenue of $3.2M

Aug 15

Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Jan 11
Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Aug 18
Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

LogicBio EPS misses by $0.06, beats on revenue

May 10

LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo

Apr 27

Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Apr 12
Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

Mar 08
Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

Jan 15
The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

LogicBio extends collaboration with Children's Medical Research Institute

Jan 07

LogicBio Therapeutics names new CFO

Dec 22

Looking In On LogicBio

Nov 17

LogicBio reports Q3 results

Nov 09

Analyse de la situation financière

Passif à court terme: LOGC's short term assets ($32.8M) exceed its short term liabilities ($16.4M).

Passif à long terme: LOGC's short term assets ($32.8M) exceed its long term liabilities ($6.4M).


Historique et analyse du ratio d'endettement

Niveau d'endettement: LOGC has more cash than its total debt.

Réduire la dette: Insufficient data to determine if LOGC's debt to equity ratio has reduced over the past 5 years.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: LOGC has sufficient cash runway for more than a year based on its current free cash flow.

Prévisions de trésorerie: LOGC has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 15.8% each year.


Découvrir des entreprises saines